The HPRA advises healthcare professionals not to retain printed versions of Summary of Product Characteristics (SPC) documents. As these documents are subject to frequent content updates, including changes to safety and dose related information, we recommend that you visit our website as necessary to access the most up-to-date versions. If you have any queries about specific SPCs on our website then please e-mail

Relenza 5mg/dose, inhalation powder, pre-dispensed

5 milligram(s)/dose Powder for Inhalation

GlaxoSmithKline (Ireland) LimitedPA1077/011/001

Main Information

Trade NameRelenza 5mg/dose, inhalation powder, pre-dispensed
Active SubstancesZanamivir
Strength5 milligram(s)/dose
Dosage FormPowder for Inhalation
Licence HolderGlaxoSmithKline (Ireland) Limited
Licence NumberPA1077/011/001

Group Information

ATC CodeJ05AH Neuraminidase inhibitors
J05AH01 zanamivir


Licence Issued07/07/1999
Legal statusProduct subject to prescription which may not be renewed (A)
Supply StatusSupply through pharmacies only
Advertising StatusAdvertising to healthcare professionals only
Conditions of Licence
Marketing StatusNot marketed


Summary of Product CharacteristicsPDF Version
Package LeafletPDF Version
Public Assessment ReportNo document available
« Back